The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drug–Drug Interactions in Humans

  • Jashvant D. Unadkat
  • Brian J. Kirby
  • Christopher J. Endres
  • Joseph K. Zolnerciks


Drug transport proteins have been recognized as significant contributors to drug absorption, distribution, elimination, toxicity, and efficacy. This chapter will discuss the key concepts of transporter-based drug–drug interactions (DDIs), provide a concise review of DDIs involving the major drug transporters, and describe methodologies used to quantitatively predict the magnitude of transporter-based DDIs in humans.


Breast Cancer Resistance Protein Canalicular Membrane Biliary Clearance Equilibrative Transporter Efflux Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by NIH grants GM032165 and GM54447. Brian Kirby was supported in part by an ARCS fellowship and an NIH Pharmacological Sciences training grant (GM07550).


  1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S and Yawo H (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–17163.PubMedCrossRefGoogle Scholar
  2. Adibi SA (1997) The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology 113:332–340.PubMedCrossRefGoogle Scholar
  3. Allen JD, Brinkhuis RF, Wijnholds J and Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237–4241.PubMedGoogle Scholar
  4. Asberg A, Hartmann A, Fjeldsa E, Bergan S and Holdaas H (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382–386.PubMedCrossRefGoogle Scholar
  5. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD and Fairbairn LJ (2003) Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol 285:C584–C591.PubMedGoogle Scholar
  6. Backman JT, Kyrklund C, Kivisto KT, Wang JS and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122–129.PubMedCrossRefGoogle Scholar
  7. Backman JT, Kyrklund C, Neuvonen M and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–691.PubMedCrossRefGoogle Scholar
  8. Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B and Gill M (2008) Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 28:883–894.PubMedCrossRefGoogle Scholar
  9. Bernacki J, Dobrowolska A, Nierwinska K and Malecki A (2008) Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 60:600–622.PubMedGoogle Scholar
  10. Boll M, Markovich D, Weber WM, Korte H, Daniel H and Murer H (1994) Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors. Pflugers Arch 429:146–149.PubMedCrossRefGoogle Scholar
  11. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T and Bates SE (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938–5946.PubMedGoogle Scholar
  12. Choi MK and Song IS (2008) Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 23:243–253.PubMedCrossRefGoogle Scholar
  13. Choudhuri S and Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231–259.PubMedCrossRefGoogle Scholar
  14. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S and Sugiyama Y (1999) Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 288:735–741.PubMedGoogle Scholar
  15. Cole SP (1990) Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol 26:250–256.PubMedCrossRefGoogle Scholar
  16. Cooper CL, van Heeswijk RP, Gallicano K and Cameron DW (2003) A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:1585–1592.PubMedCrossRefGoogle Scholar
  17. Cordon-Cardo C, O‘Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695–698.PubMedCrossRefGoogle Scholar
  18. Cundy KC (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36:127–143.PubMedCrossRefGoogle Scholar
  19. Dallas S, Miller DS and Bendayan R (2006) Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 58:140–161.PubMedCrossRefGoogle Scholar
  20. Davit-Spraul A, Gonzales E, Baussan C and Jacquemin E (2009) Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 4:1.PubMedCrossRefGoogle Scholar
  21. de Boer AG, van der Sandt ICJ and Gaillard PJ (2003) The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 43:629–656.PubMedCrossRefGoogle Scholar
  22. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G and Haefeli WE (2004) Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76:73–84.PubMedCrossRefGoogle Scholar
  23. Drayer DE, Romankiewicz J, Lorenzo B and Reidenberg MM (1982) Age and renal clearance of cimetidine. Clin Pharmacol Ther 31:45–50.PubMedCrossRefGoogle Scholar
  24. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ and Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604.PubMedCrossRefGoogle Scholar
  25. Eilers M, Roy U and Mondal D (2008) MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood) 233:1149–1160.CrossRefGoogle Scholar
  26. Ekins S, Durst GL, Stratford RE, Thorner DA, Lewis R, Loncharich RJ and Wikel JH (2001) Three-dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication. J Chem Inf Comput Sci 41:1578–1586.PubMedGoogle Scholar
  27. Endres CJ, Hsiao P, Chung FS and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501–517.PubMedCrossRefGoogle Scholar
  28. Eyal S, Hsiao P and Unadkat JD (2009) Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123(1):80-104PubMedCrossRefGoogle Scholar
  29. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231.PubMedCrossRefGoogle Scholar
  30. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 83:567–576.PubMedCrossRefGoogle Scholar
  31. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA and Lee CA (2009) Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173–181.PubMedCrossRefGoogle Scholar
  32. Funk C, Ponelle C, Scheuermann G and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627–635.PubMedGoogle Scholar
  33. Geick A, Eichelbaum M and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587.PubMedCrossRefGoogle Scholar
  34. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046–10050.PubMedCrossRefGoogle Scholar
  35. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG and Kim RB (2007) Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362–370.PubMedCrossRefGoogle Scholar
  36. Govindarajan R (2002) Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park) 16:23–26.Google Scholar
  37. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von RO, Zundler J and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153.PubMedCrossRefGoogle Scholar
  38. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665.PubMedCrossRefGoogle Scholar
  39. Haimeur A, Conseil G, Deeley RG and Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21–53.PubMedCrossRefGoogle Scholar
  40. Hardamn JG, Limbird LE and Gilman AG (2001) Goodman and Gilman’s The pharmacological Basis of Therapeutics. McGraw-Hill.Google Scholar
  41. He L and Liu GQ (2002) Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin 23:423–429.PubMedGoogle Scholar
  42. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M and Schenck-Gustafsson K (1991) Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49:256–262.PubMedCrossRefGoogle Scholar
  43. Hedman A, Angelin B, Arvidsson A, Dahlqvist R and Nilsson B (1990) Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47:20–26.PubMedCrossRefGoogle Scholar
  44. Herrine SK and Choudhary C (1999) Severe hepatotoxicity associated with troglitazone. Ann Intern Med 130:163–164.PubMedGoogle Scholar
  45. Hinderling PH and Hartmann D (1991) Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 13:381–401.PubMedCrossRefGoogle Scholar
  46. Hirano H, Kurata A, Onishi Y, Sakurai A, Saito H, Nakagawa H, Nagakura M, Tarui S, Kanamori Y, Kitajima M and Ishikawa T (2006) High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 3:252–265.PubMedCrossRefGoogle Scholar
  47. Hirano M, Maeda K, Hayashi H, Kusuhara H and Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876–882.PubMedCrossRefGoogle Scholar
  48. Horikawa M, Kato Y, Tyson CA and Sugiyama Y (2002) The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17:23–33.PubMedCrossRefGoogle Scholar
  49. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–37168.PubMedCrossRefGoogle Scholar
  50. Hsiao P, Bui T, Ho RJ and Unadkat JD (2008) In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 36:481–484.PubMedCrossRefGoogle Scholar
  51. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC and Unadkat JD (2006) Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704–710.PubMedCrossRefGoogle Scholar
  52. Huang L (2009) Role of drug transporters in the disposition of statins. AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside, Parsippany, NJ. 2005. Ref Type: Conference ProceedingGoogle Scholar
  53. Iwanaga T, Nakakariya M, Yabuuchi H, Maeda T and Tamai I (2007) Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol Pharm Bull 30:739–744.PubMedCrossRefGoogle Scholar
  54. Jalava KM, Partanen J and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609–613.PubMedCrossRefGoogle Scholar
  55. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651–1656.PubMedCrossRefGoogle Scholar
  56. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162.PubMedCrossRefGoogle Scholar
  57. Kajosaari LI, Laitila J, Neuvonen PJ and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249–256.PubMedCrossRefGoogle Scholar
  58. Kruh GD and Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537–7552.PubMedCrossRefGoogle Scholar
  59. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K and Belinsky MG (2001) MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33:493–501.PubMedCrossRefGoogle Scholar
  60. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943–2950.PubMedCrossRefGoogle Scholar
  61. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525–533.PubMedCrossRefGoogle Scholar
  62. Kusuhara H and Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37–52.PubMedCrossRefGoogle Scholar
  63. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J and Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340–345.PubMedCrossRefGoogle Scholar
  64. Lacarelle B, Rahmani R, de SG, Durand A, Placidi M and Cano JP (1991) Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 5:567–582.PubMedCrossRefGoogle Scholar
  65. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J and Martin JC (1995) (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171:788–796.PubMedGoogle Scholar
  66. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL and Jaffe HS (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126:257–263.PubMedGoogle Scholar
  67. Lau YY, Huang Y, Frassetto L and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.PubMedCrossRefGoogle Scholar
  68. Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V and Leibach FH (1995) Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem 270:6456–6463.PubMedCrossRefGoogle Scholar
  69. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 ( Pt 11 ):2011-2021.PubMedGoogle Scholar
  70. Loi CM, Young M, Randinitis E, Vassos A and Koup JR (1999) Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91–104.PubMedCrossRefGoogle Scholar
  71. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559–4563.PubMedGoogle Scholar
  72. Marzolini C and Kim RB (2005) Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 78:118–122.PubMedCrossRefGoogle Scholar
  73. Mathias AA, Hitti J and Unadkat JD (2005) P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 289:R963–R969.PubMedGoogle Scholar
  74. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug–drug interaction caused by cimetidine. Drug Metab Dispos 37:555–559.PubMedCrossRefGoogle Scholar
  75. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G and Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28B–32B.PubMedCrossRefGoogle Scholar
  76. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J and Abe T (2004a) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101:3569–3574.PubMedCrossRefGoogle Scholar
  77. Mikkaichi T, Suzuki T, Tanemoto M, Ito S and Abe T (2004b) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171–179.PubMedCrossRefGoogle Scholar
  78. Mirski SE, Gerlach JH and Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594–2598.PubMedGoogle Scholar
  79. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF and Sugiyama Y (2006) Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575–1581.PubMedCrossRefGoogle Scholar
  80. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C and Laine K (2005) Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 78:123–131.PubMedCrossRefGoogle Scholar
  81. Nagashige M, Ushigome F, Koyabu N, Hirata K, Kawabuchi M, Hirakawa T, Satoh S, Tsukimori K, Nakano H, Uchiumi T, Kuwano M, Ohtani H and Sawada Y (2003) Basal membrane localization of MRP1 in human placental trophoblast. Placenta 24:951–958.PubMedCrossRefGoogle Scholar
  82. Niemi M, Backman JT, Fromm MF, Neuvonen PJ and Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819–850.PubMedCrossRefGoogle Scholar
  83. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102:17923–17928.PubMedCrossRefGoogle Scholar
  84. Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK and Groothuis GM (1995) Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1241:215–268.PubMedGoogle Scholar
  85. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S and Jaross W (2001) Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 6:351–361.PubMedCrossRefGoogle Scholar
  86. Park S and Sinko PJ (2005) P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249–1256.PubMedCrossRefGoogle Scholar
  87. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter BF, Scheper RJ, Tytgat GN, Borst P, Baas F and Oude Elferink RP (1997) A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539–1542.PubMedCrossRefGoogle Scholar
  88. Pedersen KE, Christiansen BD, Klitgaard NA and Nielsen-Kudsk F (1983) Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 24:41–47.PubMedCrossRefGoogle Scholar
  89. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V and Falloon J (2004) Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 26:322–330.PubMedCrossRefGoogle Scholar
  90. Reidenberg MM, Camacho M, Kluger J and Drayer DE (1980) Aging and renal clearance of procainamide and acetylprocainamide. Clin Pharmacol Ther 28:732–735.PubMedCrossRefGoogle Scholar
  91. Roberts DH, Kendall MJ, Jack DB and Welling PG (1981) Pharmacokinetics of cephradine given intravenously with and without probenecid. Br J Clin Pharmacol 11:561–564.PubMedGoogle Scholar
  92. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145–152.PubMedGoogle Scholar
  93. Russel FG, Masereeuw R and van Aubel RA (2002) Molecular aspects of renal anionic drug transport. Annu Rev Physiol 64:563–594.PubMedCrossRefGoogle Scholar
  94. Sasaki M, Suzuki H, Ito K, Abe T and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497–6503.PubMedCrossRefGoogle Scholar
  95. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503–514.PubMedCrossRefGoogle Scholar
  96. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Walk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE and Borst P (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94:4028–4033.PubMedCrossRefGoogle Scholar
  97. Schinkel AH, Mol CA, Wagenaar E, van DL, Smit JJ and Borst P (1995) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295–1298.PubMedCrossRefGoogle Scholar
  98. Schinkel AH, Smit JJ, Van TO, Beijnen JH, Wagenaar E, van DL, Mol CA, van der valk MA, Robanus-Maandag EC, Teriele HP et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502.PubMedCrossRefGoogle Scholar
  99. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455–463.PubMedCrossRefGoogle Scholar
  100. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K and Ieiri I (2007) Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52:117–122.PubMedCrossRefGoogle Scholar
  101. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM and Giacomini KM (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273–280.PubMedCrossRefGoogle Scholar
  102. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM and Giacomini KM (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431.PubMedCrossRefGoogle Scholar
  103. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–177.PubMedCrossRefGoogle Scholar
  104. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA and Benet LZ (1999) Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 16:478–485.PubMedCrossRefGoogle Scholar
  105. Somogyi A, McLean A and Heinzow B (1983) Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 25:339–345.PubMedCrossRefGoogle Scholar
  106. Somogyi A, Rohner HG and Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5:84–94.PubMedCrossRefGoogle Scholar
  107. Somogyi A, Stockley C, Keal J, Rolan P and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545–551.PubMedGoogle Scholar
  108. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH and Shin JG (2008a) Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559–562.PubMedCrossRefGoogle Scholar
  109. Song IS, Shin HJ and Shin JG (2008b) Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 38:1252–1262.PubMedCrossRefGoogle Scholar
  110. Srimaroeng C, Perry JL and Pritchard JB (2008) Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 38:889–935.PubMedCrossRefGoogle Scholar
  111. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S and Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48:1926–1929.PubMedGoogle Scholar
  112. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251–260.PubMedCrossRefGoogle Scholar
  113. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77–85.PubMedCrossRefGoogle Scholar
  114. Terada T, Saito H and Inui K (1998) Interaction of beta-lactam antibiotics with histidine residue of rat H+/peptide cotransporters, PEPT1 and PEPT2. J Biol Chem 273:5582–5585.PubMedCrossRefGoogle Scholar
  115. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735–7738.PubMedCrossRefGoogle Scholar
  116. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159–164.PubMedGoogle Scholar
  117. Thummel KE, Shen DD, Soherranen N and Mith HE (2006) Design and optimization of dosage regimens; pharmacokinetic data, in Goodman & Gilman’s the Pharmacological Basis of Therapeutics (Goodman LS, Gilman A, Brunton LL, Lazo JS and Parker KL eds) pp 1787–1887, McGraw-Hill, New York.Google Scholar
  118. Tirona RG, Leake BF, Wolkoff AW and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223–228.PubMedCrossRefGoogle Scholar
  119. Treiber A, Schneiter R, Hausler S and Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–1407.PubMedCrossRefGoogle Scholar
  120. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T and Inui K (2009) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185–191.PubMedCrossRefGoogle Scholar
  121. Unadkat JD, Dahlin A and Vijay S (2004) Placental drug transporters. Curr Drug Metab 5:125–131.PubMedCrossRefGoogle Scholar
  122. Uwai Y, Ida H, Tsuji Y, Katsura T and Inui K (2007) Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 24:811–815.PubMedCrossRefGoogle Scholar
  123. van Giersbergen PL, Halabi A and Dingemanse J (2002) Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53:589–595.PubMedCrossRefGoogle Scholar
  124. van Giersbergen PL, Popescu G, Bodin F and Dingemanse J (2003) Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 43:15–22.PubMedCrossRefGoogle Scholar
  125. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H and Dingemanse J (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81:414–419.PubMedCrossRefGoogle Scholar
  126. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR and Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944–3948.PubMedGoogle Scholar
  127. Wang JS, Neuvonen M, Wen X, Backman JT and Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352–1356.PubMedCrossRefGoogle Scholar
  128. Wang ZJ, Yin OQ, Tomlinson B and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genom 18:637–645.CrossRefGoogle Scholar
  129. Weiner IM, Washington JA and Mudge GH (1960) On the mechanism of action of probenecid on renal tubular secretion. Bull Johns Hopkins Hosp 106:333–346.PubMedGoogle Scholar
  130. Wen X, Wang JS, Backman JT, Kivisto KT and Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359–1361.PubMedGoogle Scholar
  131. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK and Siegmund W (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6–12.PubMedCrossRefGoogle Scholar
  132. Woodland C, Ito S and Koren G (1998) A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit 20:134–138.PubMedCrossRefGoogle Scholar
  133. Wright SH and Dantzler WH (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84:987–1049.PubMedCrossRefGoogle Scholar
  134. Yang H and Elmquist WF (1996) The binding of cyclosporin A to human plasma: an in vitro microdialysis study. Pharm Res 13:622–627.PubMedCrossRefGoogle Scholar
  135. Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M and Zhou SF (2006a) Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide. Curr Drug Metab 7:431–455.PubMedCrossRefGoogle Scholar
  136. Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M, Sheu FS, Zhang Q, Bian JS, Chan E, Li X, Wang JC and Zhou SF (2006b) A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther 319:82–104.PubMedCrossRefGoogle Scholar
  137. Yasui-Furukori N, Uno T, Sugawara K and Tateishi T (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77:17–23.PubMedCrossRefGoogle Scholar
  138. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG and Gerlach JH (1999) Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5:673–680.PubMedGoogle Scholar
  139. Zhang L, Zhang YD, Strong JM, Reynolds KS and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–724.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jashvant D. Unadkat
    • 1
  • Brian J. Kirby
    • 2
  • Christopher J. Endres
    • 2
  • Joseph K. Zolnerciks
    • 2
  1. 1.Department of Pharmaceutics, School of PharmacyUniversity of WashingtonSeattleUSA
  2. 2.Department of PharmaceuticsUniversity of WashingtonSeattleUSA

Personalised recommendations